Ask AI
ProCE Banner Activity

CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach

Podcast Episodes

Learn about the emerging role of CDH6-targeting antibody–drug conjugates for ovarian cancer with Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard MD, PhD, discussing the latest results and implications of studies evaluating raludotatug deruxtecan and other agents.

Released: November 05, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Daiichi Sankyo, Inc and Merck Sharp & Dohme, LLC

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Disclosure

Primary Author

Kathleen N. Moore, MD, MS, FASCO: consultant/advisor/speaker: Aadi, AbbVie, AstraZeneca, BioNTech, Blueprint, Caris, Corcept, Daiichi Sankyo, Duality, Eisai, Genentech/Roche, GSK, Immunogen, Janssen, Loxo-Lilly, Merck, Mersana, Novartis, Regeneron, Schrödinger, Takeda, Verastem, Whitehawk, Zentalis.

Isabelle Ray-Coquard, MD, PhD, Prof, has no relevant financial relationships to disclose.